Mechthild Krause

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8031877/publications.pdf

Version: 2024-02-01

220 papers	10,562 citations	29994 54 h-index	39575 94 g-index
241 all docs	241 docs citations	241 times ranked	12536 citing authors

#	Article	IF	Citations
1	Exploring the role of cancer stem cells in radioresistance. Nature Reviews Cancer, 2008, 8, 545-554.	12.8	766
2	Radiation oncology in the era of precision medicine. Nature Reviews Cancer, 2016, 16, 234-249.	12.8	636
3	ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. Radiotherapy and Oncology, 2015, 114, 3-10.	0.3	462
4	Cancer stem cells: Radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments. Advanced Drug Delivery Reviews, 2017, 109, 63-73.	6.6	247
5	Human gastric cancer modelling using organoids. Gut, 2019, 68, 207-217.	6.1	204
6	Aldehyde Dehydrogenase Is Regulated by Î²-Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells. Cancer Research, 2015, 75, 1482-1494.	0.4	195
7	Î²1 Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy. Journal of Clinical Investigation, 2012, 122, 1529-1540.	3.9	194
8	CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG). International Journal of Cancer, 2016, 138, 171-181.	2.3	184
9	EGFR-targeted anti-cancer drugs in radiotherapy: Preclinical evaluation of mechanisms. Radiotherapy and Oncology, 2007, 83, 238-248.	0.3	170
10	Three-Dimensional Cell Growth Confers Radioresistance by Chromatin Density Modification. Cancer Research, 2010, 70, 3925-3934.	0.4	165
11	A comparative study of machine learning methods for time-to-event survival data for radiomics risk modelling. Scientific Reports, 2017, 7, 13206.	1.6	163
12	ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, version 1.1. Radiotherapy and Oncology, 2016, 118, 205-208.	0.3	162
13	Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiotherapy and Oncology, 2004, 72, 257-266.	0.3	161
14	Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial. Journal of Clinical Oncology, 2020, 38, 3615-3625.	0.8	155
15	Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation. Radiotherapy and Oncology, 2007, 83, 304-310.	0.3	144
16	HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiotherapy and Oncology, 2014, 113, 317-323.	0.3	141
17	A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiotherapy and Oncology, 2008, 88, 258-268.	0.3	130
18	HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiotherapy and Oncology, 2016, 121, 364-373.	0.3	130

#	Article	IF	Citations
19	Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(â^) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG. Clinical Cancer Research, 2016, 22, 2639-2649.	3.2	127
20	Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging. Radiotherapy and Oncology, 2017, 124, 533-540.	0.3	123
21	European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. Lancet Oncology, The, 2022, 23, e21-e31.	5.1	117
22	Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. Lancet Oncology, The, 2018, 19, e240-e251.	5.1	108
23	Cancer Stem Cells: Targets and Potential Biomarkers for Radiotherapy. Clinical Cancer Research, 2011, 17, 7224-7229.	3.2	106
24	EGF Receptor Inhibition Radiosensitizes NSCLC Cells by Inducing Senescence in Cells Sustaining DNA Double-Strand Breaks. Cancer Research, 2011, 71, 6261-6269.	0.4	105
25	Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: The need for a multivariate approach in biomarker studies. Radiotherapy and Oncology, 2006, 81, 122-129.	0.3	102
26	Repopulation of FaDu human squamous cell carcinoma during fractionated radiotherapy correlateswith reoxygenation. International Journal of Radiation Oncology Biology Physics, 2001, 51, 483-493.	0.4	101
27	Clinical Implementation of Dual-energy CT for Proton Treatment Planning on Pseudo-monoenergetic CT scans. International Journal of Radiation Oncology Biology Physics, 2017, 97, 427-434.	0.4	98
28	Cancer stem cells at the crossroads of current cancer therapy failuresâ€"Radiation oncology perspective. Seminars in Cancer Biology, 2010, 20, 116-124.	4.3	97
29	Relative biological effectiveness in proton beam therapy â€“ Current knowledge and future challenges. Clinical and Translational Radiation Oncology, 2018, 9, 35-41.	0.9	96
30	CD44: A Cancer Stem Cellâ€"Related Biomarker with Predictive Potential for Radiotherapy. Clinical Cancer Research, 2010, 16, 5091-5093.	3.2	93
31	The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). International Journal of Cancer, 2017, 141, 594-603.	2.3	91
32	Identification of Patient Benefit From Proton Therapy for Advanced Head and Neck Cancer Patients Based on Individual and Subgroup Normal Tissue Complication Probability Analysis. International Journal of Radiation Oncology Biology Physics, 2015, 92, 1165-1174.	0.4	89
33	Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas. Oncotarget, 2017, 8, 109228-109237.	0.8	89
34	Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation. Radiotherapy and Oncology, 2005, 76, 162-167.	0.3	85
35	â€œRadiobiology of Proton Therapyâ€: Results of an international expert workshop. Radiotherapy and Oncology, 2018, 128, 56-67.	0.3	85
36	Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontinâ€"EGFR Pathway. Cancer Research, 2017, 77, 2018-2028.	0.4	80

#	Article	IF	Citations
37	Creating a data exchange strategy for radiotherapy research: Towards federated databases and anonymised public datasets. Radiotherapy and Oncology, 2014, 113, 303-309.	0.3	79
38	Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy. Radiotherapy and Oncology, 2006, 80, 112-122.	0.3	78
39	Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression. Radiotherapy and Oncology, 2011, 99, 323-330.	0.3	78
40	Simultaneous Î²1 integrin-EGFR Targeting and Radiosensitization of Human Head and Neck Cancer. Journal of the National Cancer Institute, 2015, 107, .	3.0	78
41	Cancer stem cells and radiotherapy. International Journal of Radiation Biology, 2009, 85, 391-402.	1.0	75
42	Prediction of clonogenic cell survival curves based on the number of residual DNA double strand breaks measured by Î³H2AX staining. International Journal of Radiation Biology, 2009, 85, 1032-1041.	1.0	70
43	GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy. Theranostics, 2021, 11, 7844-7868.	4.6	70
44	Individualization of cancer treatment from radiotherapy perspective. Molecular Oncology, 2012, 6, 211-221.	2.1	68
45	Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. Lancet Haematology,the, 2018, 5, e161-e169.	2.2	67
46	A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV Infection. Clinical Cancer Research, 2019, 25, 1505-1516.	3.2	67
47	Combination of EGFR/HER2 Tyrosine Kinase Inhibition by BIBW 2992 and BIBW 2669 with Irradiation in FaDu Human Squamous Cell Carcinoma. Strahlentherapie Und Onkologie, 2007, 183, 256-264.	1.0	64
48	Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy. Pharmaceuticals, 2014, 7, 311-338.	1.7	62
49	An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells. Cancer Research, 2016, 76, 2637-2651.	0.4	62
50	Comparative analysis of transcriptomics based hypoxia signatures in head- and neck squamous cell carcinoma. Radiotherapy and Oncology, 2016, 118, 350-358.	0.3	62
51	Tumour irradiation in mice with a laser-accelerated proton beam. Nature Physics, 2022, 18, 316-322.	6.5	62
52	EGFR-Mediated Chromatin Condensation Protects KRAS-Mutant Cancer Cells against Ionizing Radiation. Cancer Research, 2014, 74, 2825-2834.	0.4	61
53	DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity. Seminars in Radiation Oncology, 2015, 25, 237-250.	1.0	59
54	Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure. Acta OncolÃ³gica, 2015, 54, 1355-1363.	0.8	57

#	Article	IF	Citations
55	Pre-clinical research in small animals using radiotherapy technology â€“ a bidirectional translational approach. Zeitschrift Fur Medizinische Physik, 2014, 24, 335-351.	0.6	54
56	Radiotherapy and "new" drugs-new side effects?. Radiation Oncology, 2011, 6, 177.	1.2	53
57	Cetuximab Attenuates Its Cytotoxic and Radiosensitizing Potential by Inducing Fibronectin Biosynthesis. Cancer Research, 2013, 73, 5869-5879.	0.4	53
58	The CD98 Heavy Chain Is a Marker and Regulator of Head and Neck Squamous Cell Carcinoma Radiosensitivity. Clinical Cancer Research, 2019, 25, 3152-3163.	3.2	53
59	EGFR-TK inhibition before radiotherapy reduces tumour volume but does not improve local control: Differential response of cancer stem cells and nontumourigenic cells?. Radiotherapy and Oncology, 2007, 83, 316-325.	0.3	51
60	Heat shock protein 70 and tumorâ€infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTKâ€ROG). International Journal of Cancer, 2018, 142, 1911-1925.	2.3	50
61	GTV differentially impacts locoregional control of non-small cell lung cancer (NSCLC) after different fractionation schedules: Subgroup analysis of the prospective randomized CHARTWEL trial. Radiotherapy and Oncology, 2013, 106, 299-304.	0.3	49
62	Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic potential. Radiotherapy and Oncology, 2014, 110, 362-369.	0.3	49
63	The extreme radiosensitivity of the squamous cell carcinoma SKX is due to a defect in double-strand break repair. Radiotherapy and Oncology, 2009, 90, 257-264.	0.3	48
64	In vivo studies of the PARP inhibitor, AZD-2281, in combination with fractionated radiotherapy: An exploration of the therapeutic ratio. Radiotherapy and Oncology, 2015, 116, 486-494.	0.3	48
65	Photon vs. proton radiochemotherapy: Effects on brain tissue volume and perfusion. Radiotherapy and Oncology, 2018, 128, 121-127.	0.3	48
66	Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest. Radiotherapy and Oncology, 2015, 115, 120-127.	0.3	47
67	Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice. International Journal of Radiation Oncology Biology Physics, 2005, 61, 908-914.	0.4	46
68	Development and Validation of a Gene Signature for Patients with Head and Neck Carcinomas Treated by Postoperative Radio(chemo)therapy. Clinical Cancer Research, 2018, 24, 1364-1374.	3.2	45
69	CT imaging during treatment improves radiomic models for patients with locally advanced head and neck cancer. Radiotherapy and Oncology, 2019, 130, 10-17.	0.3	44
70	Reduction of clinical safety margins in proton therapy enabled by the clinical implementation of dual-energy CT for direct stopping-power prediction. Radiotherapy and Oncology, 2022, 166, 71-78.	0.3	44
71	Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: Possible role for thrombosis. Radiotherapy and Oncology, 2007, 82, 96-104.	0.3	43
72	Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation. Anticancer Research, 2003, 23, 3869-76.	0.5	43

#	Article	IF	Citations
73	Individual patient data meta-analysis of FMISO and FAZA hypoxia PET scans from head and neck cancer patients undergoing definitive radio-chemotherapy. Radiotherapy and Oncology, 2020, 149, 189-196.	0.3	41
74	Does heterogeneity of pimonidazole labelling correspond to the heterogeneity of radiation-response of FaDu human squamous cell carcinoma?. Radiotherapy and Oncology, 2005, 76, 206-212.	0.3	40
75	Residual DNA double strand breaks in perfused but not in unperfused areas determine different radiosensitivity of tumours. Radiotherapy and Oncology, 2011, 100, 137-144.	0.3	40
76	Internal and external validation of an ESTRO delineation guideline â€“ dependent automated segmentation tool for loco-regional radiation therapy of early breast cancer. Radiotherapy and Oncology, 2016, 121, 424-430.	0.3	40
77	Precise image-guided irradiation of small animals: a flexible non-profit platform. Physics in Medicine and Biology, 2016, 61, 3084-3108.	1.6	39
78	Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: Differences between antibodies and TK inhibitors. International Journal of Radiation Biology, 2009, 85, 943-954.	1.0	38
79	Cellular and Tumor Radiosensitivity is Correlated to Epidermal Growth Factor Receptor Protein Expression Level in Tumors Without EGFR Amplification. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1181-1188.	0.4	38
80	Î³H2AX assay in ex vivo irradiated tumour specimens: A novel method to determine tumour radiation sensitivity in patient-derived material. Radiotherapy and Oncology, 2015, 116, 473-479.	0.3	38
81	Does the uncertainty in relative biological effectiveness affect patient treatment in proton therapy?. Radiotherapy and Oncology, 2021, 163, 177-184.	0.3	38
82	Residual Î³H2AX foci predict local tumour control after radiotherapy. Radiotherapy and Oncology, 2013, 108, 434-439.	0.3	37
83	Independent validation of a new reirradiation risk score (RRRS) for glioma patients predicting post-recurrence survival: A multicenter DKTK/ROG analysis. Radiotherapy and Oncology, 2018, 127, 121-127.	0.3	37
84	Impact of waiting time after surgery and overall time of postoperative radiochemotherapy on treatment outcome in glioblastoma multiforme. Radiation Oncology, 2015, 10, 172.	1.2	36
85	NTCP reduction for advanced head and neck cancer patients using proton therapy for complete or sequential boost treatment versus photon therapy. Acta OncolÃ³gica, 2015, 54, 1658-1664.	0.8	36
86	Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?. European Urology, 2019, 75, 548-551.	0.9	36
87	Radioresistance of KRAS/TP53â€mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo. International Journal of Cancer, 2020, 147, 472-477.	2.3	36
88	Low-dose hyperradiosensitivity of human glioblastoma cell linesin vitrodoes not translate into improved outcome of ultrafractionated radiotherapyin vivo. International Journal of Radiation Biology, 2005, 81, 751-758.	1.0	35
89	Effect of [18F]FMISO stratified dose-escalation on local control in FaDu hSCC in nude mice. Radiotherapy and Oncology, 2014, 111, 81-87.	0.3	34
90	Reâ€irradiation of recurrent gliomas: pooled analysis and validation of an established prognostic scoreâ€”report of the Radiation Oncology Group (<scp>ROG</scp>) of the German Cancer Consortium (<scp>DKTK</scp>). Cancer Medicine, 2018, 7, 1742-1749.	1.3	34

#	Article	IF	Citations
91	2D and 3D convolutional neural networks for outcome modelling of locally advanced head and neck squamous cell carcinoma. Scientific Reports, 2020, 10, 15625.	1.6	34
92	Profile of European proton and carbon ion therapy centers assessed by the EORTC facility questionnaire. Radiotherapy and Oncology, 2017, 124, 185-189.	0.3	33
93	Early and late effects of radiochemotherapy on cerebral blood flow in glioblastoma patients measured with non-invasive perfusion MRI. Radiotherapy and Oncology, 2016, 118, 24-28.	0.3	32
94	Independent validation of tumour volume, cancer stem cell markers and hypoxia-associated gene expressions for HNSCC after primary radiochemotherapy. Clinical and Translational Radiation Oncology, 2019, 16, 40-47.	0.9	32
95	Effect of cetuximab and fractionated irradiation on tumour micro-environment. Radiotherapy and Oncology, 2010, 97, 322-329.	0.3	28
96	Kinetics of EGFR expression during fractionated irradiation varies between different human squamous cell carcinoma lines in nude mice. Radiotherapy and Oncology, 2005, 76, 151-156.	0.3	27
97	Effects of Lovastatin Alone or Combined with Irradiation on Tumor Cells in Vitro and in Vivo. Strahlentherapie Und Onkologie, 2008, 184, 48-53.	1.0	27
98	Comparison study of in vivo dose response to laser-driven versus conventional electron beam. Radiation and Environmental Biophysics, 2015, 54, 155-166.	0.6	27
99	Development and validation of NTCP models for acute side-effects resulting from proton beam therapy of brain tumours. Radiotherapy and Oncology, 2019, 130, 164-171.	0.3	27
100	Oct4 confers stemness and radioresistance to head and neck squamous cell carcinoma by regulating the homologous recombination factors PSMC3IP and RAD54L. Oncogene, 2021, 40, 4214-4228.	2.6	27
101	Clinical biomarkers of kinase activity: examples from EGFR inhibition trials. Cancer and Metastasis Reviews, 2008, 27, 387-402.	2.7	26
102	Epidermal growth factor receptor inhibitors for radiotherapy: biological rationale and preclinical results. Journal of Pharmacy and Pharmacology, 2010, 60, 1019-1028.	1.2	26
103	Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo. Radiotherapy and Oncology, 2012, 102, 444-449.	0.3	26
104	Research Facility for Radiobiological Studies at the University Proton Therapy Dresden. International Journal of Particle Therapy, 2018, 5, 172-182.	0.9	26
105	Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomographyâ€“staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial. European Urology Oncology, 2022, 5, 44-51.	2.6	26
106	Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy. Radiotherapy and Oncology, 2019, 135, 43-50.	0.3	25
107	UniCAR T cell immunotherapy enables efficient elimination of radioresistant cancer cells. OncoImmunology, 2020, 9, 1743036.	2.1	25
108	SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. Radiotherapy and Oncology, 2018, 126, 125-131.	0.3	24

#	Article	IF	Citations
109	Neurocognitive function and quality of life after proton beam therapy for brain tumour patients. Radiotherapy and Oncology, 2020, 143, 108-116.	0.3	24
110	Metastatic Spread in Prostate Cancer Patients Influencing Radiotherapy Response. Frontiers in Oncology, 2020, 10, 627379.	1.3	24
111	Molecular targeting in radiotherapy of lung cancer. Lung Cancer, 2004, 45, S187-S197.	0.9	23
112	Independent validation of the prognostic value of cancer stem cell marker expression and hypoxia-induced gene expression for patients with locally advanced HNSCC after postoperative radiotherapy. Clinical and Translational Radiation Oncology, 2016, 1, 19-26.	0.9	22
113	Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model. OncoImmunology, 2017, 6, e1342909.	2.1	22
114	German Cancer Consortium (DKTK) â€“ A national consortium for translational cancer research. Molecular Oncology, 2019, 13, 535-542.	2.1	22
115	EGFR-amplification plus gene expression profiling predicts response to combined radiotherapy with EGFR-inhibition: A preclinical trial in 10 HNSCC-tumour-xenograft models. Radiotherapy and Oncology, 2017, 124, 496-503.	0.3	21
116	Recovery from sublethal damage during fractionated irradiation of human FaDu SCC. Radiotherapy and Oncology, 2005, 74, 331-336.	0.3	20
117	PRONTOX â€“ proton therapy to reduce acute normal tissue toxicity in locally advanced non-small-cell lung carcinomas (NSCLC): study protocol for a randomised controlled trial. Trials, 2016, 17, 543.	0.7	20
118	Late onset Li-Fraumeni Syndrome with bilateral breast cancer and other malignancies: case report and review of the literature. BMC Cancer, 2012, 12, 217.	1.1	19
119	Dose-guided patient positioning in proton radiotherapy using multicriteria-optimization. Zeitschrift Fur Medizinische Physik, 2019, 29, 216-228.	0.6	19
120	Comprehensive Analysis of Tumour Sub-Volumes for Radiomic Risk Modelling in Locally Advanced HNSCC. Cancers, 2020, 12, 3047.	1.7	19
121	Establishment of a small animal tumour model for in vivo studies with low energy laser accelerated particles. Radiation Oncology, 2014, 9, 57.	1.2	18
122	Increase in Tumor Control and Normal Tissue Complication Probabilities in Advanced Head-and-Neck Cancer for Dose-Escalated Intensity-Modulated Photon and Proton Therapy. Frontiers in Oncology, 2015, 5, 256.	1.3	18
123	Modeling in vivo relative biological effectiveness in particle therapy for clinically relevant endpoints. Acta OncolÃ³gica, 2017, 56, 1392-1398.	0.8	18
124	Effect of the Hypoxic Cell Sensitizer Isometronidazole on Local Control of Two Human Squamous Cell Carcinomas after Fractionated Irradiation. Strahlentherapie Und Onkologie, 2004, 180, 375-382.	1.0	17
125	Ultrafractionation does not Improve the Results of Radiotherapy in Radioresistant Murine DDL1 Lymphoma. Strahlentherapie Und Onkologie, 2005, 181, 540-544.	1.0	17
126	Neoadjuvant radiochemotherapy decreases the total amount of tumor infiltrating lymphocytes, but increases the number of CD8+/Granzyme B+ (GrzB) cytotoxic T-cells in rectal cancer. OncoImmunology, 2018, 7, e1393133.	2.1	17

#	Article	IF	Citations
127	Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC. Radiotherapy and Oncology, 2018, 127, 27-35.	0.3	17
128	Concept for individualized patient allocation: ReCompareâ€"remote comparison of particle and photon treatment plans. Radiation Oncology, 2014, 9, 59.	1.2	16
129	SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy. Clinical and Translational Radiation Oncology, 2017, 5, 28-36.	0.9	16
130	High-precision image-guided proton irradiation of mouse brain sub-volumes. Radiotherapy and Oncology, 2020, 146, 205-212.	0.3	16
131	Late Side Effects in Normal Mouse Brain Tissue After Proton Irradiation. Frontiers in Oncology, 2020, 10, 598360.	1.3	16
132	Potential clinical predictors of outcome after postoperative radiotherapy of non-small cell lung cancer. Strahlentherapie Und Onkologie, 2014, 190, 263-269.	1.0	15
133	Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients. Journal of Neuro-Oncology, 2015, 124, 197-205.	1.4	15
134	Development of a genetic sensor that eliminates p53 deficient cells. Nature Communications, 2017, 8, 1463.	5.8	15
135	Applying Tissue Slice Culture in Cancer Researchâ€"Insights from Preclinical Proton Radiotherapy. Cancers, 2020, 12, 1589.	1.7	15
136	Refinement of the Hounsfield lookâ€up table by retrospective application of patientâ€specific direct proton stoppingâ€power prediction from dualâ€energy CT. Medical Physics, 2020, 47, 1796-1806.	1.6	15
137	Final Results of the Prospective Biomarker Trial PETra: [11C]-MET-Accumulation in Postoperative PET/MRI Predicts Outcome after Radiochemotherapy in Glioblastoma. Clinical Cancer Research, 2021, 27, 1351-1360.	3.2	15
138	Simultaneous PLK1 inhibition improves local tumour control after fractionated irradiation. Radiotherapy and Oncology, 2013, 108, 422-428.	0.3	14
139	FMISO-PET-based lymph node hypoxia adds to the prognostic value of tumor only hypoxia in HNSCC patients. Radiotherapy and Oncology, 2019, 130, 97-103.	0.3	14
140	Personalized Radiation Oncology: Epidermal Growth Factor Receptor and Other Receptor Tyrosine Kinase Inhibitors. Recent Results in Cancer Research, 2016, 198, 107-122.	1.8	12
141	Toward Distributed Conduction of Large-Scale Studies in Radiation Therapy and Oncology: Open-Source System Integration Approach. IEEE Journal of Biomedical and Health Informatics, 2016, 20, 1397-1403.	3.9	12
142	Increased FDG uptake on late-treatment PET in non-tumour-affected oesophagus is prognostic for pathological complete response and disease recurrence in patients undergoing neoadjuvant radiochemotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1813-1822.	3.3	12
143	Quality assessment of delineation and dose planning of early breast cancer patients included in the randomized Skagen Trial 1. Radiotherapy and Oncology, 2017, 123, 282-287.	0.3	12
144	Pre-clinical imaging for establishment and comparison of orthotopic non-small cell lung carcinoma: in search for models reflecting clinical scenarios. British Journal of Radiology, 2019, 92, 20180539.	1.0	12

#	Article	IF	Citations
145	Dose dependent cerebellar atrophy in glioma patients after radio(chemo)therapy. Radiotherapy and Oncology, 2020, 150, 262-267.	0.3	12
146	Radiotherapy enhances uptake and efficacy of 90Y-cetuximab: A preclinical trial. Radiotherapy and Oncology, 2021, 155, 285-292.	0.3	12
147	Ultrafractionation in human malignant glioma xenografts. International Journal of Cancer, 2003, 107, 333-333.	2.3	11
148	Proton radiography for inline treatment planning and positioning verification of small animals. Acta OncolÃ³gica, 2017, 56, 1399-1405.	0.8	11
149	Tumor heterogeneity determined with a Î³H2AX foci assay: A study in human head and neck squamous cell carcinoma (hHNSCC) models. Radiotherapy and Oncology, 2017, 124, 379-385.	0.3	11
150	Comparable radiation response of ex vivo and in vivo irradiated tumor samples determined by residual Î³H2AX. Radiotherapy and Oncology, 2019, 139, 94-100.	0.3	11
151	Early and late side effects, dosimetric parameters and quality of life after proton beam therapy and IMRT for prostate cancer: a matched-pair analysis. Acta OncolÃ³gica, 2019, 58, 916-925.	0.8	11
152	Radiomics-based tumor phenotype determination based on medical imaging and tumor microenvironment in a preclinical setting. Radiotherapy and Oncology, 2022, 169, 96-104.	0.3	11
153	FDG uptake in normal tissues assessed by PET during treatment has prognostic value for treatment results in head and neck squamous cell carcinomas undergoing radiochemotherapy. Radiotherapy and Oncology, 2017, 122, 437-444.	0.3	10
154	Residual gammaH2AX foci in head and neck squamous cell carcinomas as predictors for tumour radiosensitivity: Evaluation in pre-clinical xenograft models and clinical specimens. Radiotherapy and Oncology, 2019, 137, 24-31.	0.3	10
155	Comparison of GeneChip, nCounter, and Real-Time PCRâ€“Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma. Journal of Molecular Diagnostics, 2020, 22, 801-810.	1.2	10
156	Results of aÂrandomized controlled phaseÂIII trial: efficacy of polyphenol-containing cystusÂ® tea mouthwash solution for the reduction of mucositis in head and neck cancer patients undergoing external beam radiotherapy. Strahlentherapie Und Onkologie, 2021, 197, 63-73.	1.0	10
157	Screening and Validation of Molecular Targeted Radiosensitizers. International Journal of Radiation Oncology Biology Physics, 2021, 111, e63-e74.	0.4	10
158	Cellular plasticity upon proton irradiation determines tumor cell radiosensitivity. Cell Reports, 2022, 38, 110422.	2.9	10
159	Clonogens and cancer stem cells. Nature Reviews Cancer, 2008, 8, 990-990.	12.8	9
160	Effect of combined irradiation and EGFR/Erb-B inhibition with BIBW 2992 on proliferation and tumour cure in cell lines and xenografts. Radiation Oncology, 2014, 9, 261.	1.2	9
161	Implementation of a software for REmote COMparison of PARticlE and photon treatment plans: ReCompare. Zeitschrift Fur Medizinische Physik, 2015, 25, 287-294.	0.6	9
162	Correlation between FMISO-PET based hypoxia in the primary tumour and in lymph node metastases in locally advanced HNSCC patients. Clinical and Translational Radiation Oncology, 2019, 15, 108-112.	0.9	9

#	Article	IF	Citations
163	Establishment and Characterisation of Heterotopic Patient-Derived Xenografts for Glioblastoma. Cancers, 2020, 12, 871.	1.7	9
164	Tyrosine Kinase c-MET as Therapeutic Target for Radiosensitization of Head and Neck Squamous Cell Carcinomas. Cancers, 2021, 13, 1865.	1.7	9
165	Comparison of the composition of lymphocyte subpopulations in non-relapse and relapse patients with squamous cell carcinoma of the head and neck before, during radiochemotherapy and in the follow-up period: a multicenter prospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiation Oncology, 2021, 16, 141.	1.2	9
166	An optimized small animal tumour model for experimentation with low energy protons. PLoS ONE, 2017, 12, e0177428.	1.1	9
167	Influence of the First Wave of the COVID-19 Pandemic on Cancer Care in a German Comprehensive Cancer Center. Frontiers in Public Health, 2021, 9, 750479.	1.3	9
168	Impact of pre- and early per-treatment FDG-PET based dose-escalation on local tumour control in fractionated irradiated FaDu xenograft tumours. Radiotherapy and Oncology, 2016, 121, 447-452.	0.3	8
169	The HIV protease and PI3K/Akt inhibitor nelfinavir does not improve the curative effect of fractionated irradiation in PC-3 prostate cancer in vitro and in vivo. Clinical and Translational Radiation Oncology, 2017, 2, 7-12.	0.9	8
170	Neoadjuvant Radiochemotherapy Significantly Alters the Phenotype of Plasmacytoid Dendritic Cells and 6-Sulfo LacNAc+ Monocytes in Rectal Cancer. Frontiers in Immunology, 2019, 10, 602.	2.2	8
171	Definition and validation of a radiomics signature for loco-regional tumour control in patients with locally advanced head and neck squamous cell carcinoma. Clinical and Translational Radiation Oncology, 2021, 26, 62-70.	0.9	8
172	Radiation oncology in the new virtual and digital era. Radiotherapy and Oncology, 2021, 154, A1-A4.	0.3	8
173	Identification of patient benefit from proton beam therapy in brain tumour patients based on dosimetric and NTCP analyses. Radiotherapy and Oncology, 2021, 160, 69-77.	0.3	8
174	Plasticity within Aldehyde Dehydrogenaseâ€“Positive Cells Determines Prostate Cancer Radiosensitivity. Molecular Cancer Research, 2022, 20, 794-809.	1.5	8
175	Adoptive transfer of cytotoxic T-cells for treatment of residual disease after irradiation. International Journal of Radiation Biology, 2007, 83, 827-836.	1.0	7
176	Long-term quality of life in inoperable non-small cell lung cancer patients treated with conventionally fractionated compared to hyperfractionated accelerated radiotherapy â€“ Results of the randomized CHARTWEL trial. Radiotherapy and Oncology, 2018, 126, 283-290.	0.3	7
177	Multi-modality bedding platform for combined imaging and irradiation of mice. Biomedical Physics and Engineering Express, 2020, 6, 037003.	0.6	7
178	Personalised radiation therapy taking both the tumour and patient into consideration. Radiotherapy and Oncology, 2022, 166, A1-A5.	0.3	7
179	TCP and NTCP in preclinical and clinical research in Europe. Rays, 2005, 30, 121-6.	0.2	7
180	Validation of CD98hc as a Therapeutic Target for a Combination of Radiation and Immunotherapies in Head and Neck Squamous Cell Carcinoma. Cancers, 2022, 14, 1677.	1.7	7

#	Article	IF	Citations
181	Local Control after Locally Ablative, Image-Guided Radiotherapy of Oligometastases Identified by Gallium-68-PSMA-Positron Emission Tomography in Castration-Sensitive Prostate Cancer Patients (OLI-P). Cancers, 2022, 14, 2073.	1.7	7
182	Experimental Evaluation of Functional Imaging for Radiotherapy. Strahlentherapie Und Onkologie, 2007, 183, 41-42.	1.0	6
183	Therapeutic options to overcome tumor hypoxia in radiation oncology. Clinical and Translational Imaging, 2017, 5, 455-464.	1.1	6
184	Specific requirements for translation of biological research into clinical radiation oncology. Molecular Oncology, 2020, 14, 1569-1576.	2.1	6
185	Combined tumor plus nontumor interim FDGâ€PET parameters are prognostic for response to chemoradiation in squamous cell esophageal cancer. International Journal of Cancer, 2020, 147, 1427-1436.	2.3	6
186	ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy. Pharmacogenomics Journal, 2021, 21, 37-46.	0.9	6
187	Modelling of late side-effects following cranial proton beam therapy. Radiotherapy and Oncology, 2021, 157, 15-23.	0.3	6
188	Tumor Biologyâ€™s Impact on Clinical Cure Rates. Medical Radiology, 2009, , 323-334.	0.0	6
189	Predicting In Vitro Cancer Cell Survival Based on Measurable Cell Characteristics. Radiation Research, 2019, 191, 532.	0.7	6
190	In regard to Solomon et al.: EGFR blockade with ZD1839 (â€œIressaâ€) potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. IJROBP 2003;55:713â€“723. International Journal of Radiation Oncology Biology Physics, 2003, 57, 300-301.	0.4	5
191	Modeling tumor control probability for spatially inhomogeneous risk of failure based on clinical outcome data. Zeitschrift Fur Medizinische Physik, 2017, 27, 285-299.	0.6	5
192	Retrospective investigation of the prognostic value of the Î²1 integrin expression in patients with head and neck squamous cell carcinoma receiving primary radio(chemo)therapy. PLoS ONE, 2018, 13, e0209479.	1.1	5
193	Heterogeneity of Î³H2AX Foci Increases in Ex Vivo Biopsies Relative to In Vivo Tumors. International Journal of Molecular Sciences, 2018, 19, 2616.	1.8	5
194	Doseâ€“volume predictors of early esophageal toxicity in non-small cell lung cancer patients treated with accelerated-hyperfractionated radiotherapy. Radiotherapy and Oncology, 2020, 143, 44-50.	0.3	5
195	Generation of biological hypotheses by functional imaging links tumor hypoxia to radiation induced tissue inflammation/glucose uptake in head and neck cancer. Radiotherapy and Oncology, 2021, 155, 204-211.	0.3	5
196	Analyses of molecular subtypes and their association to mechanisms of radioresistance in patients with HPV-negative HNSCC treated by postoperative radiochemotherapy. Radiotherapy and Oncology, 2022, 167, 300-307.	0.3	5
197	Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC â€“ Hypothesis generation on a multicentre cohort of the DKTK-ROG. Radiotherapy and Oncology, 2022, 169, 8-14.	0.3	5
198	Sample-size calculation for preclinical doseâ€“response experiments using heterogeneous tumour models. Radiotherapy and Oncology, 2021, 158, 262-267.	0.3	4

#	Article	IF	Citations
199	Molecular Response to Combined Molecular- and External Radiotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC). Cancers, 2021, 13, 5595.	1.7	4
200	Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy. Radiotherapy and Oncology, 2022, 171, 91-100.	0.3	4
201	Assessment of gene expressions from squamous cell carcinoma of the head and neck to predict radiochemotherapy-related xerostomia and dysphagia. Acta OncolÃ³gica, 2022, 61, 856-863.	0.8	4
202	Clinical trials for personalized glioblastoma radiotherapy: Markers for efficacy and late toxicity but often delayed treatment â€“ Does that matter?. Radiotherapy and Oncology, 2016, 118, 211-213.	0.3	3
203	Assembling the brain trust: the multidisciplinary imperative in neuro-oncology. Nature Reviews Clinical Oncology, 2019, 16, 521-522.	12.5	3
204	Value of functional in-vivo endpoints in preclinical radiation research. Radiotherapy and Oncology, 2021, 158, 155-161.	0.3	3
205	Efficient Heat Shock Response Affects Hyperthermia-Induced Radiosensitization in a Tumor Spheroid Control Probability Assay. Cancers, 2021, 13, 3168.	1.7	3
206	Reduced diffusion in white matter after radiotherapy with photons and protons. Radiotherapy and Oncology, 2021, 164, 66-72.	0.3	3
207	Radiotherapy and COVID-19â€"everything under control or just the start of aÂlong story?. Strahlentherapie Und Onkologie, 2020, 196, 1065-1067.	1.0	2
208	A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT. Cancers, 2022, 14, 3031.	1.7	2
209	Impact of the adaptor protein GIPC1/Synectin on radioresistance and survival after irradiation of prostate cancer. Strahlentherapie Und Onkologie, 2012, 188, 1125-1132.	1.0	1
210	Targeting PARP for Chemoradiosensitization: Opportunities, Challenges, and the Road Ahead. International Journal of Radiation Oncology Biology Physics, 2022, 112, 265-270.	0.4	1
211	Importance of long-term follow up to address long-term effectiveness and toxicity of radiotherapy. Radiotherapy and Oncology, 2022, 170, 1-3.	0.3	1
212	Epidermal growth factor receptor targeting and its role for individualisation in radiation oncology. European Journal of Cancer, Supplement, 2013, 11, 274.	2.2	0
213	Corrigendum to â€œHPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)â€• [Radiother. Oncol. 113 (2014) 317â€“323]. Radiotherapy and Oncology, 2015, 114, 419.	0.3	0
214	The Role of Cancer Stem Cells in Tumour Radioresponse. , 2016, , 43-74.		0
215	Session 39: Modelling and simulation III. Biomedizinische Technik, 2017, 62, .	0.9	0
216	A new prognostic hypoxia biomarker consisting of imaging and gene-based data. EBioMedicine, 2020, 58, 102901.	2.7	0

#	Article	IF	Citations
217	The Pluripotency Transcription Factor Oct4 Contributes to Head and Neck Squamous Cell Carcinoma Radioresistance via Regulation of DNA Repair and the Stem Cell Phenotype. Medical Sciences Forum, 2021, 3, .	0.5	0
218	In reply to the Letter to the Editor by Chen and Lui regarding â€œRadiotherapy enhances uptake and efficacy of 90Y-cetuximab: A preclinical trialâ€• by A Dietrich et al.. Radiotherapy and Oncology, 2021, 161, 261-262.	0.3	0
219	3D Semi-quantification of Nanoparticle Content in Tissue on Experimental and Commercial Î¼CT-Scanner. Springer Proceedings in Physics, 2012, , 111-115.	0.1	0
220	Subjective memory impairment in glioma patients with curative radiotherapy. Radiotherapy and Oncology, 2022, , .	0.3	0